Pfizer Japan Inc. seemed to prefer to highlight aspects of its business other than sales performance at a Tokyo media briefing, pointing to expected growth for selected products and generics, a new structure, its R&D pipeline, and extensive corporate responsibility activities.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?